Viatris buys Pacira for $1.65B to expand non-opioid pain portfolio
Viatris agreed to acquire Pacira BioSciences in an all-cash deal valued at $1.65 billion. The purchase adds commercial non-opioid pain products and continues recent dealmaking in the pain sector.
Viatris is set to take over Pacira BioSciences through an all-cash transaction worth $1.65 billion. The move would add marketed non-opioid pain therapies to Viatris’s lineup. It continues a trend of recent transactions in the pain-treatment field.
If completed, the acquisition could affect patients who need non-opioid pain options, clinicians who prescribe them, and employees of both companies. It may also influence how pain treatments are developed or made available, though outcomes are uncertain. Rival firms and investors could react, potentially shaping further deal activity. Whether the deal ultimately benefits society may depend on continued access and innovation in pain care.